Elevance Health, Inc. (ELV)
NYSE: ELV · Real-Time Price · USD
377.95
+1.97 (0.52%)
May 28, 2025, 4:00 PM - Market closed
Elevance Health Stock Forecast
Stock Price Forecast
According to 15 professional analysts, the 12-month price target for Elevance Health stock ranges from a low of $405.4 to a high of $631. The average analyst price target of $519.76 forecasts a 37.52% increase in the stock price over the next year.
Price Target: $519.76 (+37.52%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 23, 2025.
Analyst Ratings
The average analyst rating for Elevance Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
Buy | 9 | 9 | 9 | 9 | 8 | 8 |
Hold | 1 | 2 | 2 | 2 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 14 | 15 | 15 | 15 | 15 | 15 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy Reiterates $478 | Buy | Reiterates | $478 | +26.47% | Apr 23, 2025 |
Guggenheim | Guggenheim | Strong Buy Reiterates $518 | Strong Buy | Reiterates | $518 | +37.06% | Apr 23, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $485 | Buy | Reiterates | $485 | +28.32% | Apr 23, 2025 |
Barclays | Barclays | Buy Maintains $512 → $522 | Buy | Maintains | $512 → $522 | +38.11% | Apr 23, 2025 |
Baird | Baird | Buy → Hold Downgrades $625 → $529 | Buy → Hold | Downgrades | $625 → $529 | +39.97% | Apr 15, 2025 |
Financial Forecast
Revenue This Year
196.54B
from 176.81B
Increased by 11.16%
Revenue Next Year
210.55B
from 196.54B
Increased by 7.13%
EPS This Year
34.77
from 25.68
Increased by 35.39%
EPS Next Year
39.73
from 34.77
Increased by 14.29%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 208.8B | 221.5B | 242.7B | |
Avg | 196.5B | 210.6B | 227.0B | |
Low | 189.1B | 201.8B | 213.9B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|
High | 18.1% | 12.7% | 15.3% | |
Avg | 11.2% | 7.1% | 7.8% | |
Low | 6.9% | 2.7% | 1.6% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 36.33 | 43.68 | 49.61 | ||
Avg | 34.77 | 39.73 | 45.51 | ||
Low | 33.09 | 37.61 | 42.39 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 41.5% | 25.6% | 24.9% | ||
Avg | 35.4% | 14.3% | 14.5% | ||
Low | 28.9% | 8.2% | 6.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.